Pharmacological Onomastics: What's in a name?

British Journal of Pharmacology

Volumn 153, Issue 3, 2008, Pages 432-438

  Kenakin, T P ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Drug classification; Drug nomenclature; Receptor agonists and antagonists

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; APLAVIROC; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ARRESTIN; CLOZAPINE; DEACETYLLEVONANTRADOL; GUANINE NUCLEOTIDE BINDING PROTEIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MIANSERIN; OPIATE AGONIST; PROPRANOLOL; RITANSERIN; SEROTONIN ANTAGONIST;

ALLOSTERISM; CELL FUNCTION; CELL TYPE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG RECEPTOR BINDING; LIGAND BINDING; NOMENCLATURE; NONHUMAN; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; ULCER;

ALLOSTERIC REGULATION; DRUG AGONISM; DRUG ANTAGONISM; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; PHARMACEUTICAL PREPARATIONS; TERMINOLOGY AS TOPIC;

EID: 38849136696     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707407     Document Type: Review

References (53)

1. Aloyo VJ, Dave KD, Rahman T, Harvey JA (2001). Selective and divergent regulation of cortical 5-HT2A receptors in rabbit. J Pharmacol Exp Ther 299: 1066-1072.
2. Azzi M, Charest PG, Angers S, Rousseau G, Kohout TA (2003). arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G-protein-coupled receptors. Proc Natl Acad Sci USA 100: 11406-11411.
3. 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64: 1357-1369.
4. Beyermann M, Heinrich N, Fechner K, Ferkurt J, Zhang W, Kraetke O et al. (2007). Ago-antagonists for G protein-coupled peptide hormone receptor by modifying the agonist's signaling domain. Br J Pharmacol 151: 851-859.
5. 2A receptors during endocytosis. J Biol Chem 276: 8269-8277.
6. Bouvier M (2001). Oligomerization of G-protein-coupled transmitter receptors. Nat Rev Neurosci 2: 274-286.
7. Chidiac P, Nouet P, Bouvier M (1996). Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor. Mol Pharmacol 50: 662-666.
8. Costa T, Herz A (1989). Antagonists with negative intrinsic activity at δ-opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci 86: 7321-7325.
9. Costa T, Klinz FJ, Vachon L, Herz A (1988). Opioid receptors are coupled tightly to G proteins but loosely to adenylate cyclase in NG108-15 cell membranes. Mol Pharmacol 34: 744-754.
10. 2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70: 1575-1584.
11. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S et al. (2006). Distinct β-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 281: 10856-10864.
12. 2-adrenergic receptor: evidence for ligand specific conformational changes. J Biol Chem 270: 28268-28275.
13. 2-adrenergic receptor. J Biol Chem 276: 24433-24436.
14. Giepmans BNG, Adams SR, Ellisman MH, Tsien RY (2006). Review - The fluorescent toolbox for assessing protein location and function. Science 312: 217-224.
15. Goldstein JM (2000). The new generation of antipsychotic drugs: how atypical are they? Int J Neuropsychopharmacol 3: 339-349.
16. 2A receptors by agonists and antagonists. Brain Res Bull 56: 441-451.
17. Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE et al. (2007). An opioid agonist that does not induce m-opioid receptor-arrestin interactions or receptor internalization. Mol Pharmacol 71: 549-557.
18. Jakubic J, Bacakova L, Lisa V, El-Fakahany EE, Tucek S (1997). Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 52: 172-179.
19. Kenakin TP (1995b). Pharmacological proteus. Trends Pharmacol Sci 16: 256-258.
20. Kenakin TP, Onaran O (2002). The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol Sci 23: 275-280.
21. Kenakin TP (1995a). Agonist-receptor efficacy II: agonist trafficking of receptor signals. Trends Pharmacol Sci 16: 232-238.
22. Kenakin TP (2001). Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15: 598-611.
23. Kenakin TP (2002). Efficacy at G protein coupled receptors. Annu Rev Pharmacol Toxicol 42: 349-379.
24. Kenakin TP (2004). MiniReview: efficacy as a vector : the prevalence and paucity of inverse agonism. Mol Pharmacol 65: 2-11.
25. Kenakin TP (2006). Collateral efficacy as pharmacological problem applied to new drug discovery. Expert Opin Drug Disc 1: 635-652.
26. Lefkowitz RJ (2004). Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol Sci 25: 413-422.
27. Lefkowitz RJ, Rajagopal K, Whalen EJ (2006). New roles for beta-arrestins in cell signaling: not just seven-transmembrane receptors [Review]. Mol Cell 24: 643-652.
28. Lefkowitz RJ, Shenoy SK (2005). Transduction of receptor signals by β-arrestins. Science 308: 512-517.
29. Legros J-L (2001). Inhibitory effect of oxytocin on corticotrope function in humans: are vasopressin and oxytocin ying-yang neurohormones? Psychoneuroendocrinology 26: 649-655.
30. Li IT, Pham E, Truong K (2006). Protein biosensors based on the principle of fluorescence resonance energy transfer for monitoring cellular dynamics. Biotechnol Lett 28: 1971-1982.
31. Littman BH, De Mario L, Plebani M, Marincolas FM (2007). What's next in translational medicine? Clin Sci 112: 217-227.
32. Luttrell LM (2005). Composition and function of G protein-coupled receptor signalsomes controlling mitogen-activated protein kinase activity. J Mol Neurosci 26: 253-263.
33. Mackinnon AC, Waters C, Jodrell D, Haslett C, Sethi T (2001). Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. J Biol Chem 276: 28083-28091.
34. Marie N, Aguila B, Allouche S (2006). Tracking the opioid receptors on the way of desensitization. Cell Signal 18: 1815-1833.
35. Milligan G, Bond RA (1997). Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18: 468-474.
36. Mukhopadhyay S, Howlett AC (2005). Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol 67: 2016-2024.
37. Onaran HO, Costa T (1997). Agonist efficacy and allosteric models of receptor action. Ann NY Acad Sci 812: 98-115.
38. Onaran HO, Scheer A, Cotecchia S, Costa T (2000). A look at receptor efficacy. From the signaling network of the cell to the intramolecular motion of the receptor. In: Kenakin TP, Angus JA (eds). The Pharmacology of Functional, Biochemical, and Recombinant Systems Handbook of Experimental Pharmacology, vol 148. Springer, Heidelberg: Germany, pp 217-280.
39. Palanche T, Ilien B, Zoffmann S, Reck MP, Nucher B, Edelstein SJ et al. (2001). The Neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J Biol Chem 276: 34853-34861.
40. Persani L, Calebiro D, Bonomi M (2007). Technology Insight: modern methods to monitor protein-protein interactions reveal functional TSH receptor oligomerization. Nat Clin Pract Endocrin Metab 3: 180-190.
41. Pfleger KDG, Eidne KA (2006). Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET). Nat Methods 3: 165-174.
42. Ribot-Ciscar E, Roll JP (1998). Ago-antagonist muscle spindle inputs contribute together to joint movement coding in man. Brain Res 791: 167-176.
43. Sachpatzidis A, Benton BK, Manfredi JP, Wang H, Hamilton A, Dohlman HG et al. (2003). Identification of allosteric peptide agonists. J Biol Chem 278: 896-907.
44. Schwartz TW, Holst B (2006). Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Recept Signal Transduct Res 26: 107-128.
45. Smit MJ, Leurs R, Alewijnse AE, Blauw J, Amerongen GPV, Vandevrede Y et al. (1996). Inverse agonism of histamine H-2 antagonists accounts for up-regulation of spontaneously active histamine H-2 receptors. Proc Natl Acad Sci USA 93: 6802-6807.
46. Stephenson RP (1956). A modification of receptor theory. Br J Pharmacol 11: 379-393.
47. 2-adrenoceptor. Kinetic evidence for intermediate conformation states. J Biol Chem 279: 686-691.
48. Terrillon S, Bouvier M (2004). Receptor activity-independent recruitment of β-arrestin reveals specific signaling modes. EMBO J 23: 3950-3961.
49. Urban JD, Clarke WP, Zastrow M, Nichols DE, Kobilka B, Weinstein H et al. (2007). Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
50. Watson C, Chen G, Irving PE, Way J, Chen W-J, Kenakin TP (2000). The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists. Mol Pharmacol 58: 1230-1238.
51. Watson C, Jenkinson S, Kazmierski W, Kenakin TP (2005). The CCR5 Receptor-based mechanism of action of 873140, a potent allosteric non-competitive HIV entry-inhibitor. Mol Pharmacol 67: 1268-1282.
52. Wells TNC, Power CA, Shaw JP, Proudfoot AEI (2006). Chemokine blockers-therapeutics in the making? Trends Pharmacol Sci 27: 42-47.
53. Willins DL, Berry SA, Alsayegh L, Backstrom L, Sander-Bush E, Friedman L et al. (1999). Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. Neuroscience 91: 599-606.